298 related articles for article (PubMed ID: 22647738)
1. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.
Lee LY; Sanderson JD; Irving PM
Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1078-85. PubMed ID: 22647738
[TBL] [Abstract][Full Text] [Related]
2. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
3. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
4. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
[TBL] [Abstract][Full Text] [Related]
6. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
Ebert EC; Das KM; Mehta V; Rezac C
Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
[TBL] [Abstract][Full Text] [Related]
7. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.
Steenholdt C; Palarasah Y; Bendtzen K; Teisner A; Brynskov J; Teisner B; Nielsen CH
Aliment Pharmacol Ther; 2013 Jun; 37(12):1172-83. PubMed ID: 23650912
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.
O'Meara S; Nanda KS; Moss AC
Inflamm Bowel Dis; 2014 Jan; 20(1):1-6. PubMed ID: 24280879
[TBL] [Abstract][Full Text] [Related]
9. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
Imaeda H; Andoh A; Fujiyama Y
J Gastroenterol; 2012 Feb; 47(2):136-43. PubMed ID: 21953314
[TBL] [Abstract][Full Text] [Related]
10. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
11. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
[TBL] [Abstract][Full Text] [Related]
12. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
[TBL] [Abstract][Full Text] [Related]
13. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
[TBL] [Abstract][Full Text] [Related]
14. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.
Ben-Horin S; Waterman M; Kopylov U; Yavzori M; Picard O; Fudim E; Awadie H; Weiss B; Chowers Y
Clin Gastroenterol Hepatol; 2013 Apr; 11(4):444-7. PubMed ID: 23103905
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
16. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
Nanda KS; Cheifetz AS; Moss AC
Am J Gastroenterol; 2013 Jan; 108(1):40-7; quiz 48. PubMed ID: 23147525
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
18. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
Khanna R; Sattin BD; Afif W; Benchimol EI; Bernard EJ; Bitton A; Bressler B; Fedorak RN; Ghosh S; Greenberg GR; Marshall JK; Panaccione R; Seidman EG; Silverberg MS; Steinhart AH; Sy R; Van Assche G; Walters TD; Sandborn WJ; Feagan BG
Aliment Pharmacol Ther; 2013 Sep; 38(5):447-59. PubMed ID: 23848220
[TBL] [Abstract][Full Text] [Related]
19. [Perspectives in inflammatory bowel diseases treatment].
Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
[TBL] [Abstract][Full Text] [Related]
20. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
